A large observational study suggested that weekly tumor board participation by oncologists improves survival in advanced lung and colorectal cancers, increases participation in clinical trials, and leads to greater use of guideline-based curative care for early non–small cell lung cancer.

This is an observational study only, and it is difficult to quantify the direct effect of tumor board participation.

It is likely that facilities that sponsor tumor boards have improved expertise to deliver high-quality care, so participation may not be directly related to improved outcomes. ■